Ignite Creation Date:
2025-12-25 @ 1:45 AM
Ignite Modification Date:
2026-01-22 @ 1:04 PM
Study NCT ID:
NCT03116594
Status:
COMPLETED
Last Update Posted:
2017-04-17
First Post:
2017-04-12
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006562', 'term': 'Herpes Zoster'}], 'ancestors': [{'id': 'D000073618', 'term': 'Varicella Zoster Virus Infection'}, {'id': 'D006566', 'term': 'Herpesviridae Infections'}, {'id': 'D004266', 'term': 'DNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D007239', 'term': 'Infections'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D053061', 'term': 'Herpes Zoster Vaccine'}], 'ancestors': [{'id': 'D019433', 'term': 'Chickenpox Vaccine'}, {'id': 'D022283', 'term': 'Herpesvirus Vaccines'}, {'id': 'D014765', 'term': 'Viral Vaccines'}, {'id': 'D014612', 'term': 'Vaccines'}, {'id': 'D001688', 'term': 'Biological Products'}, {'id': 'D045424', 'term': 'Complex Mixtures'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2', 'PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 675}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2014-01-03', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2017-04', 'completionDateStruct': {'date': '2015-03-07', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2017-04-12', 'studyFirstSubmitDate': '2017-04-12', 'studyFirstSubmitQcDate': '2017-04-12', 'lastUpdatePostDateStruct': {'date': '2017-04-17', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2017-04-17', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2014-04-08', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'GMR(Geometric Mean Ratio) of VZV(Varicella-Zoster Virus) antibody titer measured by gpELISA(Glycoprotein Enzyme-Linked Immnosorbent Assay)', 'timeFrame': '6 weeks after IP(Investigational Product) vaccination', 'description': "The geometric mean fold rise of subjects' VZV antibody titers of NBP608 from prevaccination to 6 weeks after vaccination"}, {'measure': 'GMR(Geometric Mean Ratio) ratio of NBP608 to Zostavax measured by gpELISA(Glycoprotein Enzyme-Linked Immnosorbent Assay)', 'timeFrame': '6 weeks after IP(Investigational Product) vaccination', 'description': 'Non-inferiority assessment by comparing GMR of NBP608 to Zostavax'}], 'secondaryOutcomes': [{'measure': 'Immune response measured by gpELISA(Glycoprotein Enzyme-Linked Immnosorbent Assay)', 'timeFrame': '52 weeks after IP(Investigational Product) vaccination'}, {'measure': 'Immune response measured by IFN-γ ELISPOT(Interferon-gamma Enzyme-Linked Immunospot)', 'timeFrame': '6 weeks after IP(Investigational Product) vaccination'}, {'measure': 'Immune response measured by IFN-γ ELISPOT(Interferon-gamma Enzyme-Linked Immunospot)', 'timeFrame': '52 weeks after IP(Investigational Product) vaccination'}, {'measure': 'Immune response measured by FAMA(Fluorescent Antibody to Membrane Antigen)', 'timeFrame': '6 weeks after IP(Investigational Product) vaccination'}, {'measure': 'Immune response measured by FAMA(Fluorescent Antibody to Membrane Antigen)', 'timeFrame': '52 weeks after IP(Investigational Product) vaccination'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Herpes Zoster Vaccine', 'Prevention of Herpes Zoster'], 'conditions': ['Herpes Zoster']}, 'referencesModule': {'references': [{'pmid': '37781954', 'type': 'DERIVED', 'citation': 'de Oliveira Gomes J, Gagliardi AM, Andriolo BN, Torloni MR, Andriolo RB, Puga MEDS, Canteiro Cruz E. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev. 2023 Oct 2;10(10):CD008858. doi: 10.1002/14651858.CD008858.pub5.'}]}, 'descriptionModule': {'briefSummary': 'This study assesses non-inferiority by comparing GMR(Geometric Mean Ratio) of NBP608 to Zostavax which are evaluated by gpELISA (Glycoprotein Enzyme Linked Immunosorbent Assay). Total of 646 healthy subjects aged 50 and over are enrolled, and each subject is administered with single dose of vaccine which is randomly assigned.', 'detailedDescription': 'This is a multi-center, randomized, double blinded, parallel-group study to assess the Immunogenicity and safety of NBP608 compared to Zostavax which are indicated for the prevention of herpes zoster. Total of 646 healthy subjects aged 50 and over are enrolled, and each subject is administered with single dose of vaccine which is randomly assigned to low, high potency of NBP608 group and Zostavax group in 1:1:2 ratio. Stratified randomization for age group is used to achieve the balance of treatment assignment within age strata.\n\nTotal of six visits are scheduled including two visits via telephone contact. Blood sampling is conducted for immunogenicity assessment before and 6 weeks, 52 weeks after vaccination at Visit 2, Visit 4, Visit 6 respectively. Safety is monitored 1 week, 6 weeks, 26 weeks and 52 weeks after vaccination through Visit 3\\*, Visit 4, Visit 5\\*, Visit 6. (\\* telephone contact)'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '50 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Healthy adult over aged 50 years\n* Menopause females or females who are confirmed to be negative in a preganacy test on the day of screening and agree to practice birth control for 6 weeks after signing informed concent\n\nExclusion Criteria:\n\n* Those with hypersensitivity to any component of IP(Investigational Product), such as gelatin\n* Those with a history of hypersensitivity to vaccination, such as Guillain-Barre syndrome\n* Those who have previously received herpes zoster vaccine\n* Those who have a history of herpes zoster\n* Those with congenital or acquired immunodeficiency\n* Those with active untreated tuberculosis\n* Those who have received blood products or immunoglobulin within 3 months prior to screening visit\n* Those who have received other IPs(Investigational Products) in another clinical study witin 4 weeks prior to IP vaccination in this study'}, 'identificationModule': {'nctId': 'NCT03116594', 'briefTitle': 'Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over', 'organization': {'class': 'INDUSTRY', 'fullName': 'SK Chemicals Co., Ltd.'}, 'officialTitle': 'A Multi-center, Randomized, Double Blinded, Parallel-group Study to Assess the Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over', 'orgStudyIdInfo': {'id': 'NBP608_HZ_III_2013'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Low potency of NBP608', 'description': 'Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm', 'interventionNames': ['Biological: NBP608']}, {'type': 'EXPERIMENTAL', 'label': 'High potency of NBP608', 'description': 'Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm', 'interventionNames': ['Biological: NBP608']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Zostavax', 'description': 'Single dose 0.65mL Zostavax by subcutaneous injection into the outer aspect of the upper arm', 'interventionNames': ['Biological: Zostavax']}], 'interventions': [{'name': 'NBP608', 'type': 'BIOLOGICAL', 'description': 'Preparation of Oka/SK strain of live, attenuated zoster virus', 'armGroupLabels': ['High potency of NBP608', 'Low potency of NBP608']}, {'name': 'Zostavax', 'type': 'BIOLOGICAL', 'description': 'Preparation of Oka/Merck strain of live, attenuated zoster virus', 'armGroupLabels': ['Zostavax']}]}, 'contactsLocationsModule': {'locations': [{'zip': '08308', 'city': 'Seoul', 'state': 'Guro-gu', 'country': 'South Korea', 'facility': 'Korea University Guro Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}], 'overallOfficials': [{'name': 'Hee-Jin Cheong, Ph.D', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Korea University Guro Hospital'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'SK Chemicals Co., Ltd.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}